Literature DB >> 23742774

Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma.

Soomin Ahn1, Jiyeon Hyeon, Cheol-Keun Park.   

Abstract

BACKGROUND: Notch signaling is critical to physiologic angiogenesis and has been implicated in tumor angiogenesis and metastasis. Notch signaling was reported to exert either oncogenic or tumor-suppressive function in hepatocellular carcinoma (HCC) tumorigenesis. However, the prognostic significance of Notch receptors in HCC remains uncertain. In this study, we investigated the roles of Notch receptors in the prognosis of HCC.
METHODS: We investigated the expressions of Notch receptors in tumor tissue microarrays of 288 patients with primary HCC who had undergone curative resection using immunohistochemistry. Additionally, prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 97.1 months. Tumor recurrence was detected in 189 patients (65.6%), and 99 (34.4%) died of HCC.
RESULTS: Cytoplasmic expression of Notch1, cytoplasmic expression of Notch3, coexistent nuclear expression of Notch3, and cytoplasmic Notch4 overexpression were observed in 145 (50.3%), 60 (20.8%), 17 (5.9%), and 172 (59.7%) of the 288 HCCs, respectively. Multivariate analyses revealed that Notch1 expression (P=0.029), Edmondson grade III (P=0.038), and higher BCLC stage (P<0.001) were independent predictors of shorter disease-free survival. Cytoplasmic Notch3 expression tended to be an independent predictor of shorter disease-free survival (P=0.055). Notch1 expression (P=0.039), Notch4 overexpression (P=0.012), and higher BCLC stage (P<0.001) were independent predictors of shorter disease-specific survival. On univariate analysis, Notch1 expression tended to show an unfavorable influence on disease-specific survival (P=0.063) and Notch4 overexpression did not show an unfavorable influence on disease-specific survival (P=0.103).
CONCLUSIONS: Notch1 expression might be an independent predictor of both shorter disease-free survival and shorter disease-specific survival in HCC patients after curative resection. Notch4 overexpression might be an independent predictor of shorter disease-specific survival. Notch1 could be used as an immunohistochemical biomarker to detect patients with a high-risk of recurrence. Notch1 and Notch4 could be used as immunohistochemical biomarkers to detect patients with a shorter disease-specific survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23742774     DOI: 10.1016/s1499-3872(13)60046-6

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  23 in total

1.  Notch4 inhibition reduces migration and invasion and enhances sensitivity to docetaxel by inhibiting Akt/fascin in pancreatic cancer cells.

Authors:  Cui-Juan Qian; Yi-Yi Chen; Xin Zhang; Fu-Qiang Liu; Ting-Ting Yue; Bei Ye; Jun Yao
Journal:  Oncol Lett       Date:  2016-09-07       Impact factor: 2.967

2.  Differential effects of targeting Notch receptors in a mouse model of liver cancer.

Authors:  Erik G Huntzicker; Kathy Hötzel; Lisa Choy; Li Che; Jed Ross; Gregoire Pau; Neeraj Sharma; Christian W Siebel; Xin Chen; Dorothy M French
Journal:  Hepatology       Date:  2015-01-28       Impact factor: 17.425

3.  Notch3 drives development and progression of cholangiocarcinoma.

Authors:  Rachel V Guest; Luke Boulter; Benjamin J Dwyer; Timothy J Kendall; Tak-Yung Man; Sarah E Minnis-Lyons; Wei-Yu Lu; Andrew J Robson; Sofia Ferreira Gonzalez; Alexander Raven; Davina Wojtacha; Jennifer P Morton; Mina Komuta; Tania Roskams; Stephen J Wigmore; Owen J Sansom; Stuart J Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

4.  Association of Notch1 with vasculogenic mimicry in human hepatocellular carcinoma cell lines.

Authors:  Man-Sheng Zhu; Lei-Bo Xu; Hong Zeng; Xiang-De Shi; Wen-Rui Wu; Chao Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.

Authors:  Wen-Rui Wu; Xiang-De Shi; Fa-Peng Zhang; Ke Zhu; Rui Zhang; Xian-Huan Yu; Yu-Fei Qin; Shun-Peng He; Hou-Wei Fu; Lei Zhang; Hong Zeng; Man-Sheng Zhu; Lei-Bo Xu; Ping-Pui Wong; Chao Liu
Journal:  Oncogene       Date:  2022-03-07       Impact factor: 9.867

6.  Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma.

Authors:  Peng Ma; Chuanxin Zou; Shitao Xia
Journal:  Immunogenetics       Date:  2022-07-27       Impact factor: 3.330

7.  Novel findings about management of gastric cancer: a summary from 10th IGCC.

Authors:  Danila Penon; Letizia Cito; Antonio Giordano
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma.

Authors:  Wen-Rui Wu; Xiang-De Shi; Rui Zhang; Man-Sheng Zhu; Lei-Bo Xu; Xian-Huan Yu; Hong Zeng; Jie Wang; Chao Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

9.  Aberrant expression of Notch1, HES1, and DTX1 genes in glioblastoma formalin-fixed paraffin-embedded tissues.

Authors:  Rajeswari Narayanappa; Pritilata Rout; Madhuri G S Aithal; Ashis Kumar Chand
Journal:  Tumour Biol       Date:  2015-12-11

10.  Xanthohumol inhibits Notch signaling and induces apoptosis in hepatocellular carcinoma.

Authors:  Selvi Kunnimalaiyaan; Kevin M Sokolowski; Mariappan Balamurugan; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.